Pereira, Philippe L.
Iezzi, Roberto
Manfredi, Riccardo
Carchesio, Francesca
Bánsághi, Zoltan
Brountzos, Elias
Spiliopoulos, Stavros
Echevarria-Uraga, Javier J.
Gonçalves, Belarmino
Inchingolo, Riccardo
Nardella, Michele
Pellerin, Olivier
Sousa, Maria
Arnold, Dirk
de Baère, Thierry
Gomez, Fernando
Helmberger, Thomas
Maleux, Geert
Prenen, Hans
Sangro, Bruno
Zeka, Bleranda
Kaufmann, Nathalie
Taieb, Julien
Clinical trials referenced in this document:
Documents that mention this clinical trial
The CIREL Cohort: A Prospective Controlled Registry Studying the Real-Life Use of Irinotecan-Loaded Chemoembolisation in Colorectal Cancer Liver Metastases: Interim Analysis
https://doi.org/10.1007/s00270-020-02646-8
Funding for this research was provided by:
Terumo Europe NV (unrestriced educational grant)
Article History
Received: 7 July 2020
Accepted: 5 September 2020
First Online: 24 September 2020
Compliance with Ethical Standards
:
: Pereira reports the receipt of grants from Siemens Healthineers, Terumo, BTG and Biocompatibles, the receipt of honoraria from Terumo, Sirtex, Angiodynamics, Medtronic, Pharmacept and Guerbet, as well as study grants from BMS, MSD, GSK and Terumo and travel support from Bayer. B. Gonçalves reports personal fees from Medtronic, personal fees from Terumo, personal fees from Sirtex, outside the submitted work. T. Helmberger received speaker honoraria from SIRTEX Medical Europe. O. Pellerin has received personal fees from Merit Medical and shareholdings of COGITh-SAS. D. Arnold received consulting fees and speaker honoraria from TERUMO, Boston Scientific, SIRTEX Medical Europe and Biocompatibles. G. Maleux received speaker fees from SIRTEX Medical Europe. B. Sangro has received personal fees from Terumo and BTG, as well as personal fees and a grant from Sirtex Medical. J. Taieb reports receiving honoraria from Merck, Roche, Amgen, Lilly, Sanofi, Samsung, MSD, Servier, Celgene, Pierre Fabre; consulting or advisory Role for Roche, Merck KGaA, Amgen, Lilly, MSD, Servier, Pierre Fabre, Sanofi, Samsung; speakers’ Bureau for Servier, Amgen, Roche, Sanofi, Merck, Lilly, Pierre Fabre. H. Prenen received honoraria and/or travel grants from Roche, Bayer, Amgen, Ipsen, Pfizer, Sanofi, Merck, Terumo and Lilly. R. Iezzi, R. Manfredi, F. Carchesio, Z. Bánsághi, E. Brountzos, S. Spiliopoulos, J. Echevarria-Uraga, R. Inchingolo, M. Nardella, M. Sousa, F. T. Debaere, Gomez, B. Zeka, and N. Kaufmann report no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
: For this type of study consent for publication is not required. However, consent for publication was obtained for every individual person’s data included in the study.